Frontera Approved to Start China Trial of Gene Therapy for Inherited Retinal Degeneration
publication date: Sep 21, 2022
Frontera Therapeutics, a US-China gene therapy company, announced its lead candidate was approved to start China trials, targeting inherited retinal degenerations with a RPE65 mutation, a rare disease. FT-001 is an AAV gene therapy candidate administered by a one-time injection into the subretinal space of the eye to deliver a functional copy of the human RPE65 gene to the nuclei ofretinal cells. The injection causes the expression of functional RPE65 proteins, improving a patient’s vision. In April, FT-001 was approved to start US trials. Frontera is headquartered in the Boston area with operations also in Suzhou. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.